Literature DB >> 24013204

Using pneumococcal carriage data to monitor postvaccination changes in invasive disease.

Daniel M Weinberger, Dana T Bruden, Lindsay R Grant, Marc Lipsitch, Katherine L O'Brien, Stephen I Pelton, Elisabeth A M Sanders, Daniel R Feikin.   

Abstract

Pneumococcal conjugate vaccines (PCVs) have been introduced worldwide. However, few developing countries have high-quality surveillance systems available for monitoring vaccine impact. We evaluated whether data from nasopharyngeal carriage studies can be used to accurately monitor post-PCV changes in the incidence of invasive pneumococcal disease (IPD) among children under 5 years of age. For various dates during 1991-2010, data on nasopharyngeal pneumococcal carriage and on IPD before and after administration of 7-valent PCV (PCV7) were available from England and Wales, the Netherlands, the Navajo and White Mountain Apache American Indian populations, and the US states of Massachusetts and Alaska. We estimated the change in carriage prevalence for each serotype in each study and then either calculated the average change (inverse variance-weighted) among vaccine and nonvaccine serotypes (model 1) or used mixed-effects models to estimate the change for each serotype individually, pooling serotype data within or between studies (models 2 and 3). We then multiplied these values by the proportion of IPD caused by each serotype during the pre-PCV7 period to obtain an estimate of post-PCV7 disease incidence. Model 1 accurately captured overall changes in IPD incidence following PCV7 introduction for most studies, while the more detailed models, models 2 and 3, were less accurate. Carriage data can be used in this simple model to estimate post-PCV changes in IPD incidence.

Entities:  

Keywords:  carriage; conjugate vaccine, pneumococcal; pneumococcus; surveillance; vaccine effectiveness; vaccines

Mesh:

Substances:

Year:  2013        PMID: 24013204      PMCID: PMC3813314          DOI: 10.1093/aje/kwt156

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  27 in total

Review 1.  Estimation of vaccine efficacy against acquisition of pneumococcal carriage.

Authors:  Hanna Rinta-Kokko; Ron Dagan; Noga Givon-Lavi; Kari Auranen
Journal:  Vaccine       Date:  2009-04-23       Impact factor: 3.641

2.  Continued impact of pneumococcal conjugate vaccine on carriage in young children.

Authors:  Susan S Huang; Virginia L Hinrichsen; Abbie E Stevenson; Sheryl L Rifas-Shiman; Ken Kleinman; Stephen I Pelton; Marc Lipsitch; William P Hanage; Grace M Lee; Jonathan A Finkelstein
Journal:  Pediatrics       Date:  2009-07       Impact factor: 7.124

3.  Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

Authors:  W P Hausdorff; J Bryant; P R Paradiso; G R Siber
Journal:  Clin Infect Dis       Date:  2000-01       Impact factor: 9.079

4.  Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial.

Authors:  Katherine L O'Brien; Eugene V Millar; Elizabeth R Zell; Melinda Bronsdon; Robert Weatherholtz; Raymond Reid; Jocelyn Becenti; Sheri Kvamme; Cynthia G Whitney; Mathuram Santosham
Journal:  J Infect Dis       Date:  2007-09-17       Impact factor: 5.226

5.  Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.

Authors:  Tamara Pilishvili; Catherine Lexau; Monica M Farley; James Hadler; Lee H Harrison; Nancy M Bennett; Arthur Reingold; Ann Thomas; William Schaffner; Allen S Craig; Philip J Smith; Bernard W Beall; Cynthia G Whitney; Matthew R Moore
Journal:  J Infect Dis       Date:  2010-01-01       Impact factor: 5.226

6.  Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members.

Authors:  Eugene V Millar; James P Watt; Melinda A Bronsdon; Jean Dallas; Raymond Reid; Mathuram Santosham; Katherine L O'Brien
Journal:  Clin Infect Dis       Date:  2008-10-15       Impact factor: 9.079

7.  Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage.

Authors:  Rosalyn J Singleton; Thomas W Hennessy; Lisa R Bulkow; Laura L Hammitt; Tammy Zulz; Debby A Hurlburt; Jay C Butler; Karen Rudolph; Alan Parkinson
Journal:  JAMA       Date:  2007-04-25       Impact factor: 56.272

8.  Impact of conjugate vaccine on transmission of antimicrobial-resistant Streptococcus pneumoniae among Alaskan children.

Authors:  Sarah Y Park; Matthew R Moore; Dana L Bruden; Terri B Hyde; Alisa L Reasonover; Marcella Harker-Jones; Karen M Rudolph; Debby A Hurlburt; Debra J Parks; Alan J Parkinson; Anne Schuchat; Thomas W Hennessy
Journal:  Pediatr Infect Dis J       Date:  2008-04       Impact factor: 2.129

9.  Outbreaks of Streptococcus pneumoniae carriage in day care cohorts in Finland - implications for elimination of transmission.

Authors:  Fabian Hoti; Panu Erästö; Tuija Leino; Kari Auranen
Journal:  BMC Infect Dis       Date:  2009-06-27       Impact factor: 3.090

10.  Invasive pneumococcal disease and 7-valent pneumococcal conjugate vaccine, the Netherlands.

Authors:  Anna M M van Deursen; Suzan P van Mens; Elisabeth A M Sanders; Bart J M Vlaminckx; Hester E de Melker; Leo M Schouls; Sabine C de Greeff; Arie van der Ende
Journal:  Emerg Infect Dis       Date:  2012-11       Impact factor: 6.883

View more
  31 in total

Review 1.  The potential impact of pneumococcal conjugate vaccine in Africa: Considerations and early lessons learned from the South African experience.

Authors:  Shabir A Madhi; Marta C Nunes
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

2.  Preventing non bacteremic pneumococcal pneumonia in older adults: historical background and considerations for choosing between PCV13 and PPV23.

Authors:  David S Fedson
Journal:  Hum Vaccin Immunother       Date:  2014-04-14       Impact factor: 3.452

3.  Long-term trends in invasive pneumococcal disease in Manitoba, Canada.

Authors:  Salaheddin M Mahmud; Hasantha Sinnock; Luiz C Mostaço-Guidolin; Gurpreet Pabla; Aleksandra K Wierzbowski; Songul Bozat-Emre
Journal:  Hum Vaccin Immunother       Date:  2017-05-11       Impact factor: 3.452

4.  Association of Nonpharmaceutical Interventions During the COVID-19 Pandemic With Invasive Pneumococcal Disease, Pneumococcal Carriage, and Respiratory Viral Infections Among Children in France.

Authors:  Alexis Rybak; Corinne Levy; François Angoulvant; Anne Auvrignon; Piotr Gembara; Kostas Danis; Sophie Vaux; Daniel Levy-Bruhl; Sylvie van der Werf; Stéphane Béchet; Stéphane Bonacorsi; Zein Assad; Andréa Lazzati; Morgane Michel; Florentia Kaguelidou; Albert Faye; Robert Cohen; Emmanuelle Varon; Naïm Ouldali
Journal:  JAMA Netw Open       Date:  2022-06-01

5.  Relating Pneumococcal Carriage Among Children to Disease Rates Among Adults Before and After the Introduction of Conjugate Vaccines.

Authors:  Daniel M Weinberger; Lindsay R Grant; Robert C Weatherholtz; Joshua L Warren; Katherine L O'Brien; Laura L Hammitt
Journal:  Am J Epidemiol       Date:  2016-05-02       Impact factor: 4.897

6.  Determining the serotype composition of mixed samples of pneumococcus using whole-genome sequencing.

Authors:  James R Knight; Eileen M Dunne; E Kim Mulholland; Sudipta Saha; Catherine Satzke; Adrienn Tothpal; Daniel M Weinberger
Journal:  Microb Genom       Date:  2021-01

7.  Genetic stability of pneumococcal isolates during 35 days of human experimental carriage.

Authors:  R A Gladstone; J F Gritzfeld; P Coupland; S B Gordon; S D Bentley
Journal:  Vaccine       Date:  2015-05-23       Impact factor: 3.641

8.  The serotype distribution among healthy carriers before vaccination is essential for predicting the impact of pneumococcal conjugate vaccine on invasive disease.

Authors:  Stefan Flasche; Olivier Le Polain de Waroux; Katherine L O'Brien; W John Edmunds
Journal:  PLoS Comput Biol       Date:  2015-04-16       Impact factor: 4.475

9.  Density and duration of experimental human pneumococcal carriage.

Authors:  J F Gritzfeld; A J H Cremers; G Ferwerda; D M Ferreira; A Kadioglu; P W M Hermans; S B Gordon
Journal:  Clin Microbiol Infect       Date:  2014-08-11       Impact factor: 8.067

10.  The PneuCarriage Project: A Multi-Centre Comparative Study to Identify the Best Serotyping Methods for Examining Pneumococcal Carriage in Vaccine Evaluation Studies.

Authors:  Catherine Satzke; Eileen M Dunne; Barbara D Porter; Keith P Klugman; E Kim Mulholland
Journal:  PLoS Med       Date:  2015-11-17       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.